← Leaderboards
Nihal Ahmad
Wm S. Middleton Memorial Veterans Hosp
$10,885,639
Attributed
$11,133,697
Total exposure
20
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $891.3K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,133,697 · 13
VA$0 · 7
By mechanism
R01$8,902,153 · 4
R21$1,098,598 · 3
P30$692,696 · 3
R03$440,250 · 3
I01$0 · 5
IK6$0 · 2
Top collaborators
- Howard H Bailey2 shared
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMelanomaApoptosisResponseBaseOverexpressionPlayMelanoma CellProteinsIn VivoTissuesPublishingMolecularFamilyMemberLeadNovel StrategiesMelanocyteSamplingNeoplasmsMouse ModelSmall MoleculeMissionIncidence
Grant awards (79)
Functional and Therapeutic Significance of PLK4 in Melanoma$547,582
R01 · FY2025 · CA · contact PI
Cancer Prevention and Control$99,420
P30 · FY2025 · CA · contact PI
Functional and Therapeutic Significance of PLK4 in Melanoma$82,457
R01 · FY2025 · CA · contact PI
Role of sirtuin 6 in melanoma development and progression$0
I01 · FY2025 · VA · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2025 · VA · contact PI
Combined inhibition of PLK1 and NOTCH for melanoma management$0
I01 · FY2025 · VA · contact PI
Functional and Therapeutic Significance of PLK4 in Melanoma$520,204
R01 · FY2024 · CA · contact PI
Cancer Prevention and Control$99,420
P30 · FY2024 · CA · contact PI
Functional and Therapeutic Significance of PLK4 in Melanoma$82,457
R01 · FY2024 · CA · contact PI
Combined inhibition of PLK1 and NOTCH for melanoma management$0
I01 · FY2024 · VA · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2024 · VA · contact PI
Role of sirtuin 6 in melanoma development and progression$0
I01 · FY2024 · VA · contact PI
Functional and Therapeutic Significance of PLK4 in Melanoma$536,631
R01 · FY2023 · CA · contact PI
Cancer Prevention and Control$99,420
P30 · FY2023 · CA · contact PI
Role of sirtuin 6 in melanoma development and progression$0
I01 · FY2023 · VA · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2023 · VA · contact PI
Combined inhibition of PLK1 and NOTCH for melanoma management$0
I01 · FY2023 · VA · contact PI
Functional and Therapeutic Significance of PLK4 in Melanoma$547,582
R01 · FY2022 · CA · contact PI
Cancer Prevention and Control Research Program$84,727
P30 · FY2022 · CA · contact PI
Role of sirtuin 6 in melanoma development and progression$0
I01 · FY2022 · VA · contact PI
Role of polo like kinase 4 in melanomagenesis and melanoma progression$0
I01 · FY2022 · VA · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2022 · VA · contact PI
Role of sirtuin 6 in melanoma development and progression$0
I01 · FY2022 · VA · contact PI
Role of SIRT3 in melanoma development and progression$0
I01 · FY2022 · VA · contact PI
Cancer Prevention and Control Research Program$103,184
P30 · FY2021 · CA · contact PI
Role of SIRT3 in melanoma development and progression$0
I01 · FY2021 · VA · contact PI
Role of SIRT3 in melanoma development and progression$0
I01 · FY2021 · VA · contact PI
BLR&D Research Career Scientist Award Application$0
IK6 · FY2021 · VA · contact PI
Role of polo like kinase 4 in melanomagenesis and melanoma progression$0
I01 · FY2021 · VA · contact PI
Cancer Prevention and Control Research Program$103,260
P30 · FY2020 · CA · contact PI
BLR&D Research Career Scientist Award Application$0
IK6 · FY2020 · VA · contact PI
Role of polo like kinase 4 in melanomagenesis and melanoma progression$0
I01 · FY2020 · VA · contact PI
Role of Polo-Like Kinase-1 in Melanocytic Transformation$454,433
R01 · FY2019 · AR · contact PI
Cancer Prevention and Control Research Program$103,265
P30 · FY2019 · CA · contact PI
BLR&D Research Career Scientist Award Application$0
IK6 · FY2019 · VA · contact PI
Role of SIRT3 in melanoma development and progression$0
I01 · FY2019 · VA · contact PI
Role of polo like kinase 4 in melanomagenesis and melanoma progression$0
I01 · FY2019 · VA · contact PI
Role of Polo-Like Kinase-1 in Melanocytic Transformation$459,704
R01 · FY2018 · AR · contact PI
Role of Polo-Like Kinase-1 in Melanocytic Transformation$39,526
R01 · FY2018 · AR · contact PI
Role of SIRT3 in melanoma development and progression$0
I01 · FY2018 · VA · contact PI
BLR&D Research Career Scientist Award Application$0
IK6 · FY2018 · VA · contact PI
Role of Polo-Like Kinase-1 in Melanocytic Transformation$395,886
R01 · FY2017 · AR · contact PI
Role of SIRT1 in melanocyte biology and melanocyte transformation$312,288
R01 · FY2017 · CA · contact PI
BLR&D Research Career Scientist Award Application$0
IK6 · FY2017 · VA · contact PI
Role of SIRT3 in melanoma development and progression$0
I01 · FY2017 · VA · contact PI
Role of Polo-Like Kinase-1 in Melanocytic Transformation$414,108
R01 · FY2016 · AR · contact PI
Role of SIRT1 in melanocyte biology and melanocyte transformation$314,176
R01 · FY2016 · CA · contact PI
Plk1-Numb Cooperation in Melanomagenesis$0
I01 · FY2016 · VA · contact PI
Role of Polo-Like Kinase-1 in Melanocytic Transformation$403,920
R01 · FY2015 · AR · contact PI
Role of SIRT1 in melanocyte biology and melanocyte transformation$314,176
R01 · FY2015 · CA · contact PI
Plk1-Numb Cooperation in Melanomagenesis$0
I01 · FY2015 · VA · contact PI
Role of SIRT1 in melanocyte biology and melanocyte transformation$316,997
R01 · FY2014 · CA · contact PI
Role of Polo-Like Kinase-1 in Melanocytic Transformation$312,702
R01 · FY2014 · AR · contact PI
Resveratrol-Zinc Combination for Prostate Cancer$158,759
R21 · FY2014 · CA · contact PI
Plk1-Numb Cooperation in Melanomagenesis$0
I01 · FY2014 · VA · contact PI
Role of SIRT1 in melanocyte biology and melanocyte transformation$312,288
R01 · FY2013 · CA · contact PI
Role of Polo-Like Kinase-1 in Melanocytic Transformation$303,130
R01 · FY2013 · AR · contact PI
Resveratrol-Zinc Combination for Prostate Cancer$196,403
R21 · FY2013 · CA · contact PI
Plk1-Numb Cooperation in Melanomagenesis$0
I01 · FY2013 · VA · contact PI
Role of Polo-Like Kinase-1 in Melanocytic Transformation$319,084
R01 · FY2012 · AR · contact PI
Role of Polo-Like Kinase-1 in Melanocytic Transformation$319,084
R01 · FY2011 · AR · contact PI
Enhancing Bioavailability of Resveratrol$187,979
R21 · FY2011 · CA · contact PI
Role of Polo-Like Kinase-1 in Melanocytic Transformation$332,379
R01 · FY2010 · AR · contact PI
Enhancing Bioavailability of Resveratrol$308,138
R21 · FY2010 · CA · contact PI
SELECT Pre-Clinical Trial of Prostate Cancer$250,774
R01 · FY2010 · CA · contact PI
SELECT Pre-Clinical Trial of Prostate Cancer$250,774
R01 · FY2009 · CA · contact PI
SELECT Pre-Clinical Trial of Prostate Cancer$250,774
R01 · FY2008 · CA · contact PI
SELECT Pre-Clinical Trial of Prostate Cancer$250,774
R01 · FY2007 · CA · contact PI
SELECT Pre-Clinical Trial of Prostate Cancer$258,263
R01 · FY2006 · CA · contact PI
Melatonin in Prostate Cancer Management$122,189
R21 · FY2006 · CA · contact PI
Melatonin in Prostate Cancer Management$125,130
R21 · FY2005 · CA
Skin Cancer Chemoprevention by Sanguinarine$72,750
R03 · FY2004 · CA
Skin Cancer Chemoprevention by Sanguinarine$72,750
R03 · FY2003 · CA
Chemoprevention of Photocarcinogenesis by Resveratrol$72,750
R03 · FY2003 · CA
Chemoprevention of Photocarcinogenesis by Resveratrol$72,750
R03 · FY2002 · CA
CHEMOPREVENTION OF PROSTATE CANCER BY SANGUINARINE$72,750
R03 · FY2002 · CA
Pilot--ODC/MAPK cell cycle regulation: photocarcinogenes$0
P30 · FY2002 · AR
CHEMOPREVENTION OF PROSTATE CANCER BY SANGUINARINE$76,500
R03 · FY2001 · CA
Pilot--ODC/MAPK cell cycle regulation: photocarcinogenes$0
P30 · FY2001 · AR